Search for content, post, videos

Immunicum enters collaboration with big pharma

Carlos de Sousa
The company will collaborate with Merck and Pfizer to evaluate ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial. Immunicum will initiate a study of ilixade
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.